echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Il-15 astigid joint card-mediated seedling treatment of bladder cancer Phase III study success rate of 72%

    Il-15 astigid joint card-mediated seedling treatment of bladder cancer Phase III study success rate of 72%

    • Last Update: 2021-02-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    IL-15 plays a vital role in the immune system by affecting natural killer cells and T cells, and N-803 is a new IL-15 hyper agonist complex, made up of IL-15 mutants (IL-15N72D) and IL-15 subjects α/IgG1 Fc fusion proteins.
    N-803 has better pharmacodynamic properties, longer presence in lymphatic tissue, and stronger anti-tumor activity than natural, non-composite IL-15 in the human body.
    previously awarded N-803 fast-track qualification based on Phase I clinical study data, and in 2019, based on Phase II clinical studies, the FDA awarded N-803 breakthrough therapy.
    bladder cancer is one of the world's most common malignancies, with about 212,536 deaths from bladder cancer in 2020 and about 573,278 new confirmed cases.
    In the United States, bladder cancer is the fourth most commonly diagnosed malignant solid tumor in men, with about 75-85% of all newly diagnosed cases of bladder cancer being non-myocardial indaching bladder cancer (NMIBC) patients.
    nearly 30 years, the immunotherapy has been the standard treatment for NMIBC, however, the recurrence and progress rate of the disease is very high.
    patients with relapses, 30 percent progressed and eventually died within 15 years, and another 50 percent undercurred bladder removal to control the condition.
    Soon-Shiong, chairman and chief executive officer of ImmunityBio, said NMIBC's high rate of progress and recurrence made it one of the most overburdened cancers to treat.
    's initial treatment results are encouraging and provide evidence that N-803 is another new treatment option for NMIBC patients following a highly invasive genomic bladder excision, and we plan to submit a biological product license application for N-803 after meeting with the FDA in 2021.
    content Source: Medical Rubik's Cube Info
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.